{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:02:41Z","timestamp":1791396161214,"version":"4.3.3"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Basilea Pharmaceutica International Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Coccidioidomycosis is an invasive fungal infection that can disseminate and cause severe disease. Fosmanogepix (\u201cgepix\u201d), a first-in-class antifungal available via expanded access (NCT06433128), was successful in 8\/11 patients (meningitis, 6\/8 [75%]; nonmeningeal dissemination, 2\/3 [66%]) and was well tolerated for a median treatment duration of 208 days.<\/jats:p>","DOI":"10.1093\/cid\/ciag271","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T11:15:16Z","timestamp":1776510916000},"page":"e526-e529","source":"Crossref","is-referenced-by-count":6,"title":["Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program"],"prefix":"10.1093","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0043-0508","authenticated-orcid":false,"given":"Stuart H","family":"Cohen","sequence":"first","affiliation":[{"name":"University of California Davis Medical Center Department of Internal Medicine, Division of Infectious Diseases, , Sacramento, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3659-8732","authenticated-orcid":false,"given":"Paul","family":"Allyn","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California Los Angeles Department of Internal Medicine, Division of Infectious Diseases, , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia C","family":"Chow","sequence":"additional","affiliation":[{"name":"University of California SanFrancisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7268-5131","authenticated-orcid":false,"given":"Jennifer","family":"Rathe","sequence":"additional","affiliation":[{"name":"George Washington University School of Medicine and Health Sciences Division of Infectious Diseases, , Washington D. C. ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa D","family":"Nanayakkara","sequence":"additional","affiliation":[{"name":"City of Hope Department of Internal Medicine, Division of Infectious Diseases, , Duarte, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7237-279X","authenticated-orcid":false,"given":"Gerald","family":"Hutfles","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northwest Department of Internal Medicine, Division of Infectious Diseases, , Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1141-8261","authenticated-orcid":false,"given":"Tara","family":"Vijayan","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California Los Angeles Department of Internal Medicine, Division of Infectious Diseases, , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9186-0059","authenticated-orcid":false,"given":"Ethan A","family":"Smith","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California Los Angeles Department of Internal Medicine, Division of Infectious Diseases, , Los Angeles, California ,","place":["USA"]},{"name":"Department of Pharmaceutical Services, University of California , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher F","family":"Saling","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Mayo Clinic Arizona , Phoenix, Arizona ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0778-3901","authenticated-orcid":false,"given":"Dan","family":"Ilges","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic Arizona , Pheonix, Arizona ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haran T","family":"Schlamm","sequence":"additional","affiliation":[{"name":"HTS Pharma , San Diego, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-5750","authenticated-orcid":false,"suffix":"III","given":"George R","family":"Thompson","sequence":"additional","affiliation":[{"name":"University of California Davis Medical Center Department of Internal Medicine, Division of Infectious Diseases, , Sacramento, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2026100713425488000_ciag271-B1","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S1473-3099(21)00191-2","article-title":"Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology","volume":"21","author":"Thompson","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026100713425488000_ciag271-B2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/cid\/ciac882","article-title":"The geographic distribution of dimorphic mycoses in the United States for the modern era","volume":"76","author":"Mazi","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026100713425488000_ciag271-B3","first-page":"1","article-title":"Surveillance for coccidioidomycosis, histoplasmosis, and blastomycosis\u2014United States, 2019","volume":"71","author":"Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR)","year":"2022","journal-title":"Surveillance Summaries"},{"key":"2026100713425488000_ciag271-B4","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/jac\/dky501","article-title":"Tolerability of long-term fluconazole therapy","volume":"74","author":"Davis","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026100713425488000_ciag271-B5","doi-asserted-by":"crossref","first-page":"e02634-16","DOI":"10.1128\/AAC.02634-16","article-title":"Large-scale evaluation of in vitro amphotericin B, triazole, and echinocandin activity against coccidioides species from U.S. institutions","volume":"61","author":"Thompson","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100713425488000_ciag271-B6","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/cid\/ciad146","article-title":"Isavuconazole in the treatment of chronic forms of coccidioidomycosis","volume":"76","author":"Heidari","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026100713425488000_ciag271-B7","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1093\/mmy\/myy029","article-title":"Current concepts and future directions in the pharmacology and treatment of coccidioidomycosis","volume":"57","author":"Thompson","year":"2019","journal-title":"Med Mycol"},{"key":"2026100713425488000_ciag271-B8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/jof6040239","article-title":"Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal nfections","volume":"6","author":"Shaw","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2026100713425488000_ciag271-B9","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01623-22","article-title":"Safety and pharmacokinetics of intravenous and oral fosmanogepix, a first-in-class antifungal agent, in healthy volunteers","volume":"67","author":"Hodges","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100713425488000_ciag271-B10","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01715-18","article-title":"APX001 and other Gwt1 inhibitor prodrugs are effective in experimental coccidioides immitis pneumonia","volume":"63","author":"Viriyakosol","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100713425488000_ciag271-B11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01795-20","article-title":"Efficacy and pharmacokinetics of fosmanogepix (APX001) in the treatment of Candida endophthalmitis and hematogenous meningoencephalitis in nonneutropenic rabbits","volume":"65","author":"Petraitiene","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100713425488000_ciag271-B12","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01455-23","article-title":"Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants","volume":"68","author":"Hodges","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026100713425488000_ciag271-B13","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1093\/jac\/dkad256","article-title":"Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a phase 2 trial","volume":"78","author":"Pappas","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026100713425488000_ciag271-B14","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1093\/cid\/ciaf185","article-title":"Fosmanogepix for the treatment of invasive mold diseases caused by aspergillus species and rare molds: a phase 2, open-label study (AEGIS)","volume":"81","author":"Hodges","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026100713425488000_ciag271-B15","doi-asserted-by":"crossref","first-page":"e0141922","DOI":"10.1128\/aac.01419-22","article-title":"Clinical efficacy and safety of a novel antifungal, fosmanogepix, in patients with candidemia caused by Candida auris: results from a phase 2 trial","volume":"67","author":"Vazquez","year":"2023","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag271\/68132208\/ciag271.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/3\/e526\/68132208\/ciag271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/3\/e526\/68132208\/ciag271.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:43:00Z","timestamp":1791394980000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/83\/3\/e526\/8660495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4,21]]},"published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag271","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,15]]},"published":{"date-parts":[[2026,4,21]]}}}